RESULTS: The accuracy of the scores is described in the Table below. Based on the 95%CI, the NFS was equally accurate as the FIB-4 score, but significantly more accurate than the APRI, NIKEI and BARD scores. The FIB-4 was similar to the NIKEI and BARD scores, but significantly better than the APRI score. There was no a significant difference among the NIKEI, APRI and BARD scores. The NIKEI had the lowest indeterminate score value, but also the lowest NPV and PPV. CONCLUSIONS: This large independent validation analysis demonstrates the high accuracy of noninvasive scores to distinguish between patients with and without advanced fibrosis. Combining

the NPV and the PPV, the NFS seems the most accurate followed by the FIB-4, the APRI, the NIKEI and the BARD scores. Accuracy of the socre to distinguish between patients with

STA-9090 purchase and without advanced (stage 3/4) fibrosis AUROC (95%CI) Indeterminate score NPV (low GSK3 inhibitor cut-point) PPV (high cut-point) NFS •825 (.789,.861) 30% 89% 84% APRI .729 (.686,.771) 49% 86% 62% FIB-4 .814 (.777,.851) 29% 89% 76% NIKEI .749 (.711,.788) 1% 78% 55% BARD .744 (.702,.786) NA 78% 55% Disclosures: Charles D. Rice – Employment: Sanofi-Spouse; Management Position: SanofiSpouse; Stock Shareholder: Sanofi-Spouse Jacob George – Advisory Committees or Review Panels: Roche, BMS, MSD, Gilead, Janssen Christopher P. Day – Advisory Committees or Review Panels: Abbott; Board Membership: Abbott Paul Angulo – Grant/Research Support: NIDDK, Mochida, Genfit The following people have nothing to disclose: Elisabetta Bugianesi, Einar Bjornsson, Phunchai Charatcharoenwitthaya, Peter R. Mills Background: Recent evidence suggest that coffee consumption

could be of benefit for those In non-alcoholic fatty liver disease (NAFLD) patients at risk of developing hepatic fibrosis. The underlying mechanisms of hepatic benefits selleck kinase inhibitor of coffee intake remain unclear. Aims: a) to assess if coffee administration influences hepatic inflammation and fibrosis or mitochondrial respiration in a dietary model of non-alcoholic steatohepatitis (NASH), b) to test the effect of caffeine on hepatic stellate cells (HSC). Methods: C57bl6 mice were fed a choline-deficient amino acid-defined (CDAA) diet for 22 weeks to induce NASH. Unfiltered coffee was added to drinking water during diet administration (CDAA-C and CSAA-C groups). Hepatic steatosis, inflammation, and fibrosis were scored histologically (hematoxylin-eosin and Sirius red staining). Hepatic triglyceride content (HTG) and mRNA expression of inflammatory markers such as TNF-α and MCP-1 as well as mitochondrial respiration were assessed. In addition, primary rat HSC were culture-activated and treated with caffeine for 96h (5 to 20mM) or its main metabolite 1, 7-dimethylxanthine (1, 7-DMX) (for 72h, 1mM).